Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Glaxo Wellcome's new dihydrofolate reductase inhibitor 195U89

May 24, 1996

MGI-114 receives patent protection in U.S.

May 24, 1996

Ribonucleotide reductase inhibitor 3-AP in development at Vion

May 17, 1996

BioChem Therapeutic will codevelop VX-710 in Canada

May 17, 1996

SmithKline Beecham claims hemoregulatory agents

May 17, 1996

Mitsui Toatsu claims antitumor trifluorothymidine derivatives

May 17, 1996

Patent coverage obtained for Immune Response's cell therapy for B cell lymphoma

May 17, 1996

Supplemental NDA filed for Novantrone in U.S.

May 17, 1996

Platinum complexes claimed by Nippon Kayaku

May 17, 1996

Rb gene therapy for bladder cancer described at urology meeting

May 10, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 24, 2025.
Regulatory actions for April 24, 2025
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cel-Sci, Novavax,...
Go ask Alis? New fund aims to rescue biopharma’s trapped cash
BioWorld
“They are not zombies, they are fallen angels.” That is view of Nick Johnston, a U.K-based banker who has come up with a new plan to rescue listed companies whose...
Synthetic Design emerges with $20M and next-gen ADC platform
BioWorld
Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC)...